Circulating miRNAs in the first trimester and pregnancy complications: a systematic review.
Pregnancy
Humans
Infant, Newborn
Female
Pregnancy Trimester, First
Pre-Eclampsia
/ genetics
Hypertension, Pregnancy-Induced
/ diagnosis
Circulating MicroRNA
/ metabolism
Placenta
/ metabolism
Premature Birth
DNA Methylation
MicroRNAs
/ metabolism
Pregnancy Complications
/ metabolism
Placentation
Biomarkers
Placenta
gestational hypertension
growth restriction
miRNA
preeclampsia
pregnancy
preterm
Journal
Epigenetics
ISSN: 1559-2308
Titre abrégé: Epigenetics
Pays: United States
ID NLM: 101265293
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
pubmed:
13
12
2022
medline:
3
3
2023
entrez:
12
12
2022
Statut:
ppublish
Résumé
Most pregnancy complications originate with early placentation. MicroRNAs (miRNAs) may play an important role in placentation and function as biomarkers of future pregnancy complications. We summarized from the literature all first trimester circulating miRNAs associated with pregnancy complications of placental origin and further identified the miRNAs which have the most evidence as potential early biomarkers for pregnancy complications. We conducted a systematic review following PRISMA reporting guidelines (PROSPERO CRD42020183421). We identified all first trimester serum or plasma miRNAs associated with a pregnancy complication of placental origin (preeclampsia, intrauterine growth restriction (IUGR), gestational hypertension, preterm delivery) and the number of times those miRNAs were identified, as a measure of replication. Twenty-one studies examined 118 unique miRNAs, and 87 were associated with at least one pregnancy complication; preeclampsia was the most common. Seven miRNAs were significantly associated with a pregnancy complication in at least two studies: miR-125b, miR-518b, miR-628-3p, miR-365a-3p, miR-520h, miR-374a-5p, miR-191-5p. Few miRNAs were associated with more than one pregnancy complication: miR-518b and miR-520h with preeclampsia and gestational hypertension, miR-374a-5p and miR-191-5p with preterm birth and preeclampsia. Our systematic review suggests seven miRNAs as potential biomarkers of pregnancy complications. These complications are thought to originate with early placental defects and these miRNAs may also be biomarkers of placental pathology. First-trimester biomarkers of pregnancy complications can facilitate early detection and interventions.
Identifiants
pubmed: 36503407
doi: 10.1080/15592294.2022.2152615
pmc: PMC9980650
doi:
Substances chimiques
Circulating MicroRNA
0
MicroRNAs
0
Biomarkers
0
MIRN628 microRNA, human
0
Types de publication
Systematic Review
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2152615Subventions
Organisme : Intramural NIH HHS
ID : ZIA ES103333
Pays : United States
Références
Science. 2014 Aug 15;345(6198):760-5
pubmed: 25124429
Placenta. 2017 Mar;51:70-75
pubmed: 28292471
Front Reprod Health. 2021 Sep 23;3:719326
pubmed: 36303988
EBioMedicine. 2020 Dec;62:103145
pubmed: 33260001
Cancer Cell Int. 2018 May 01;18:64
pubmed: 29743814
PLoS One. 2014 Dec 15;9(12):e113735
pubmed: 25502889
Cell Death Discov. 2020 May 13;6:35
pubmed: 32435510
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Cancer Lett. 2019 Jun 28;452:203-212
pubmed: 30910589
Semin Fetal Neonatal Med. 2004 Oct;9(5):357-69
pubmed: 15691771
Int J Genomics. 2017;2017:8067972
pubmed: 28884117
Int J Dev Biol. 2010;54(2-3):303-12
pubmed: 19757391
Int J Mol Sci. 2013 Mar 08;14(3):5519-44
pubmed: 23528856
Biol Reprod. 2013 May 23;88(5):130
pubmed: 23575145
Placenta. 2018 Jan;61:61-71
pubmed: 29277273
J Mol Diagn. 2012 Mar-Apr;14(2):160-7
pubmed: 22251611
Sci Rep. 2014 May 08;4:4882
pubmed: 24811064
Exp Ther Med. 2019 Jul;18(1):826-832
pubmed: 31281456
PLoS One. 2017 Feb 9;12(2):e0171756
pubmed: 28182660
PLoS One. 2016 Aug 16;11(8):e0160808
pubmed: 27529341
Sci Rep. 2019 Apr 10;9(1):5861
pubmed: 30971726
Reprod Biol Endocrinol. 2021 Jul 2;19(1):100
pubmed: 34215266
Am J Obstet Gynecol. 2015 Oct;213(4 Suppl):S78-90
pubmed: 26428506
J Cell Biochem. 2013 Sep;114(9):2148-59
pubmed: 23553946
Ir J Med Sci. 2022 Jun;191(3):1251-1257
pubmed: 34159524
Mol Aspects Med. 2013 Oct;34(5):981-1023
pubmed: 23276825
J Cancer. 2020 Mar 26;11(12):3634-3644
pubmed: 32284760
Am J Pathol. 2013 Nov;183(5):1437-1445
pubmed: 24035613
Pregnancy Hypertens. 2019 Apr;16:120-125
pubmed: 31056146
Hum Exp Toxicol. 2021 Mar;40(3):439-451
pubmed: 32909851
Int J Cell Biol. 2010;2010:214074
pubmed: 20182529
Sci Rep. 2018 May 16;8(1):7680
pubmed: 29769661
Br J Obstet Gynaecol. 1986 Oct;93(10):1049-59
pubmed: 3790464
In Vivo. 2020 Sep-Oct;34(5):2317-2324
pubmed: 32871756
Cells. 2021 Apr 24;10(5):
pubmed: 33923172
Front Cell Dev Biol. 2021 Mar 11;9:646326
pubmed: 33777951
Biomed Rep. 2015 Nov;3(6):792-796
pubmed: 26623017
Arch Gynecol Obstet. 2018 Feb;297(2):365-371
pubmed: 29196869
Transl Res. 2021 Feb;228:13-27
pubmed: 32726711
Taiwan J Obstet Gynecol. 2014 Jun;53(2):232-4
pubmed: 25017274
Hypertension. 2008 Apr;51(4):970-5
pubmed: 18259009
Reproduction. 2021 Jan;161(1):F53-F65
pubmed: 32438347
Medicine (Baltimore). 2020 Feb;99(7):e18897
pubmed: 32049790
Cell Mol Immunol. 2014 Nov;11(6):538-47
pubmed: 24954225
Fertil Steril. 2014 May;101(5):1493-500
pubmed: 24786747
Front Oncol. 2021 Mar 15;11:616390
pubmed: 33791206
J Recept Signal Transduct Res. 2021 Apr;41(2):202-208
pubmed: 32787544